The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression
Sign Up to like & getrecommendations! Published in 2022 at "Acta Biochimica et Biophysica Sinica"
DOI: 10.3724/abbs.2022176
Abstract: Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),is the currently recommended first-line therapy for advanced EGFR-mutant lung cancer, and understanding the mechanism of resistance is the key to formulating therapeutic strategies for EGFR-TKIs. In… read more here.
Keywords: pseudogene duxap10; resistance nsclc; expression; gefitinib resistance ... See more keywords